Caripill Tablet Indications
Caripill (Carica papaya leaf extract) is indicated for the treatment of thrombocytopenia associated with dengue fever in both pediatric and adult patients.
Primary Indication
Thrombocytopenia in Dengue Fever
Caripill is a commercially available formulation of Carica papaya leaf extract specifically marketed for managing low platelet counts during dengue infection 1, 2. The evidence demonstrates:
Pediatric patients (1-12 years): Clinical trial data shows Caripill syrup significantly increases platelet counts starting from day 3 of treatment in children with dengue fever or dengue hemorrhagic fever grades I and II 2
- Mean platelet count increased to 89,739/μL by day 3 (p=0.030)
- Further improvement to 120,789/μL by day 4 (p=0.019)
- Reached 168,923/μL by day 5 (p=0.023)
Adult patients: While the provided evidence focuses on pediatric data, Caripill is also used in adult dengue patients with thrombocytopenia 2
Mechanism and Additional Properties
The leaf extract possesses:
- Antioxidant properties that combat oxidative stress
- Antimicrobial and anti-tumor activities 1
- Ability to reduce platelet storage lesion and maintain platelet function 1
Dosing Context
The medication is administered as:
- Syrup formulation for pediatric use
- Tablet formulation (as referenced in your question) for general use
- Given alongside standard supportive therapy for dengue management 2
Safety Profile
Caripill demonstrates excellent tolerability with minimal adverse effects - only 2 children reported nausea in clinical trials 2. The medication is well-tolerated across age groups.
Important Note: Do not confuse Caripill (papaya leaf extract) with Carvedilol or Cariprazine, which are entirely different medications with cardiovascular and psychiatric indications respectively 3, 4, 5, 6.